$CTSH
COGNIZANT TECHNOLOGY SOLUTIONS CORP Stock $ctsh

$ctsh Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000105829024000242 Filed on August 01, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue	$5.044B	$4.850B
YoY Change	3.0%	-0.74%
Cost Of Revenue	$3.311B	$3.204B
YoY Change	3.18%	-0.84%
Gross Profit	$1.733B	$1.646B
YoY Change	2.67%	-0.54%
Gross Profit Margin	34.36%	33.94%
Selling, General & Admin	$833.0M	$781.0M
YoY Change	4.0%	-5.9%
% of Gross Profit	48.07%	47.45%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$129.0M	$128.0M
YoY Change	-11.64%	-9.22%
% of Gross Profit	7.44%	7.78%
Operating Expenses	$833.0M	$781.0M
YoY Change	4.0%	-18.73%
Operating Profit	$738.0M	$708.0M
YoY Change	7.58%	2.02%
Interest Expense	$14.00M	$10.00M
YoY Change	27.27%	-9.09%
% of Operating Profit	1.9%	1.41%
Other Income/Expense, Net	$10.00M	$20.00M
YoY Change	-62.96%	-2100.0%
Pretax Income	$748.0M	$728.0M
YoY Change	4.91%	24.02%
Income Tax	$170.0M	$165.0M
% Of Pretax Income	22.73%	22.66%
Net Earnings	$582.0M	$566.0M
YoY Change	10.86%	22.25%
Net Earnings / Revenue	11.54%	11.67%
Basic Earnings Per Share	$1.17	$1.14
Diluted Earnings Per Share	$1.17	$1.14
COMMON SHARES
Basic Shares Outstanding	495.7M shares	497.2M shares
Diluted Shares Outstanding	496.0M shares	498.0M shares

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.025B	$2.205B
YoY Change	-14.48%	5.25%
Cash & Equivalents	$2.013B	$2.193B
Short-Term Investments	$12.00M	$12.00M
Other Short-Term Assets	$1.317B	$1.067B
YoY Change	38.34%	-3.09%
Inventory
Prepaid Expenses
Receivables	$4.206B	$3.973B
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$7.548B	$7.245B
YoY Change	5.91%	4.23%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.001B	$1.009B
YoY Change	-4.48%	-46.19%
Goodwill	$7.132B	$6.395B
YoY Change	18.61%	5.44%
Intangibles	$1.681B	$1.129B
YoY Change	43.19%	-8.06%
Long-Term Investments	$84.00M	$80.00M
YoY Change	20.0%	-81.18%
Other Assets	$1.034B	$1.068B
YoY Change	63.61%	-24.95%
Total Long-Term Assets	$12.62B	$11.34B
YoY Change	15.19%	2.9%
TOTAL ASSETS
Total Short-Term Assets	$7.548B	$7.245B
Total Long-Term Assets	$12.62B	$11.34B
Total Assets	$20.16B	$18.58B
YoY Change	11.53%	3.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$304.0M	$298.0M
YoY Change	-6.46%	-6.29%
Accrued Expenses	$2.696B	$2.224B
YoY Change	35.27%	18.49%
Deferred Revenue
YoY Change
Short-Term Debt	$33.00M	$33.00M
YoY Change	0.0%
Long-Term Debt Due	$33.00M	$33.00M
YoY Change	0.0%	37.5%
Total Short-Term Liabilities	$3.388B	$2.946B
YoY Change	6.17%	-3.6%
LONG-TERM LIABILITIES
Long-Term Debt	$1.183B	$590.0M
YoY Change	92.67%	-5.14%
Other Long-Term Liabilities	$440.0M	$448.0M
YoY Change	26.8%	-61.58%
Total Long-Term Liabilities	$1.623B	$1.038B
YoY Change	68.89%	-41.95%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.388B	$2.946B
Total Long-Term Liabilities	$1.623B	$1.038B
Total Liabilities	$5.712B	$4.682B
YoY Change	9.91%	-7.54%
SHAREHOLDERS EQUITY
Retained Earnings	$14.35B	$14.03B
YoY Change	9.14%	7.73%
Common Stock	$5.000M	$5.000M
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$14.45B	$13.90B
YoY Change
Total Liabilities & Shareholders Equity	$20.16B	$18.58B
YoY Change	11.53%	3.41%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income	$582.0M	$566.0M
YoY Change	10.86%	22.25%
Depreciation, Depletion And Amortization	$129.0M	$128.0M
YoY Change	-11.64%	-9.22%
Cash From Operating Activities	$847.0M	$262.0M
YoY Change	2.29%	627.78%
INVESTING ACTIVITIES
Capital Expenditures	$56.00M	$79.00M
YoY Change	-23.29%	16.18%
Acquisitions
YoY Change
Other Investing Activities	-$1.194B	$0.00
YoY Change	847.62%	-100.0%
Cash From Investing Activities	-$1.250B	-$79.00M
YoY Change	528.14%	-7.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	212.0M	-221.0M
YoY Change	-147.11%	-37.57%
NET CHANGE
Cash From Operating Activities	847.0M	262.0M
Cash From Investing Activities	-1.250B	-79.00M
Cash From Financing Activities	212.0M	-221.0M
Net Change In Cash	-191.0M	-38.00M
YoY Change	-206.7%	-90.57%
FREE CASH FLOW
Cash From Operating Activities	$847.0M	$262.0M
Capital Expenditures	$56.00M	$79.00M
Free Cash Flow	$791.0M	$183.0M
YoY Change	4.77%	-671.88%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	498000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	498000000	shares
	us-gaap	Net Income Loss NetIncomeLoss	1043000000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	273000000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-113000000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	86000000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-29000000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-50000000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	96000000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-40000000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-20000000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-447000000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	765000000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	166000000	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	37000000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2717000000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2294000000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2193000000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2055000000	usd
	us-gaap	Derivative Gain Loss Statement Of Income Or Comprehensive Income Extensible Enumeration DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#ForeignCurrencyTransactionGainLossBeforeTax
CY2024Q2	us-gaap	Derivative Gain Loss Statement Of Income Or Comprehensive Income Extensible Enumeration DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#ForeignCurrencyTransactionGainLossBeforeTax
	us-gaap	Derivative Gain Loss Statement Of Income Or Comprehensive Income Extensible Enumeration DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#ForeignCurrencyTransactionGainLossBeforeTax
CY2023Q2	us-gaap	Derivative Gain Loss Statement Of Income Or Comprehensive Income Extensible Enumeration DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#ForeignCurrencyTransactionGainLossBeforeTax
CY2024Q2	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	151000000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	13898000000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	12309000000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	580000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	77000000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	23000000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	44000000	usd
CY2023Q1	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	223000000	usd
CY2023Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.29
CY2023Q1	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	149000000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	12661000000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	463000000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	81000000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	18000000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	42000000	usd
CY2023Q2	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	215000000	usd
CY2023Q2	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.29
CY2023Q2	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	147000000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	12903000000	usd
	us-gaap	Net Income Loss NetIncomeLoss	1112000000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	266000000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-125000000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	90000000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-31000000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	121000000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	355000000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-34000000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-14000000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-493000000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	357000000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	158000000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	0	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	225000000	usd
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	0	usd
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	3000000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	3000000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	18000000	usd
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	1000000	usd
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	199000000	usd
	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	260000000	usd
	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	234000000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	421000000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	409000000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-317000000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-300000000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	35000000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	41000000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	209000000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	436000000	usd
	ctsh	Repayments Of Debt Lease And Earnout Obligations RepaymentsOfDebtLeaseAndEarnoutObligations	50000000	usd
	ctsh	Repayments Of Debt Lease And Earnout Obligations RepaymentsOfDebtLeaseAndEarnoutObligations	11000000	usd
	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	301000000	usd
	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	298000000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-525000000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-704000000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-39000000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-524000000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-239000000	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4850000000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9610000000	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4850000000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9610000000	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4850000000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9610000000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4886000000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9698000000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4886000000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9698000000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4886000000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9698000000	usd
CY2023Q4	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	245000000	usd
CY2022Q4	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	265000000	usd
	ctsh	Capitalized Contract Cost Costs Capitalized CapitalizedContractCostCostsCapitalized	35000000	usd
	ctsh	Capitalized Contract Cost Costs Capitalized CapitalizedContractCostCostsCapitalized	27000000	usd
	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	-46000000	usd
	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	-43000000	usd
CY2024Q2	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	234000000	usd
CY2023Q2	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	249000000	usd
CY2023Q4	us-gaap	Contract With Customer Asset Gross ContractWithCustomerAssetGross	316000000	usd
CY2022Q4	us-gaap	Contract With Customer Asset Gross ContractWithCustomerAssetGross	326000000	usd
	ctsh	Contract With Customer Asset Revenue Recognized But Not Billed ContractWithCustomerAssetRevenueRecognizedButNotBilled	304000000	usd
	ctsh	Contract With Customer Asset Revenue Recognized But Not Billed ContractWithCustomerAssetRevenueRecognizedButNotBilled	327000000	usd
	us-gaap	Contract With Customer Asset Reclassified To Receivable ContractWithCustomerAssetReclassifiedToReceivable	-245000000	usd
	us-gaap	Contract With Customer Asset Reclassified To Receivable ContractWithCustomerAssetReclassifiedToReceivable	-296000000	usd
	us-gaap	Contract With Customer Asset Increase Decrease For Contract Acquired In Business Combination ContractWithCustomerAssetIncreaseDecreaseForContractAcquiredInBusinessCombination	0	usd
	us-gaap	Contract With Customer Asset Increase Decrease For Contract Acquired In Business Combination ContractWithCustomerAssetIncreaseDecreaseForContractAcquiredInBusinessCombination	9000000	usd
CY2024Q2	us-gaap	Contract With Customer Asset Gross ContractWithCustomerAssetGross	375000000	usd
CY2023Q2	us-gaap	Contract With Customer Asset Gross ContractWithCustomerAssetGross	366000000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	427000000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	417000000	usd
	ctsh	Contract With Customer Liability Amount Billed But Revenue Not Recognized ContractWithCustomerLiabilityAmountBilledButRevenueNotRecognized	300000000	usd
	ctsh	Contract With Customer Liability Amount Billed But Revenue Not Recognized ContractWithCustomerLiabilityAmountBilledButRevenueNotRecognized	277000000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-316000000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-299000000	usd
	us-gaap	Contract With Customer Liability Increase Decrease For Contract Acquired In Business Combination ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination	9000000	usd
	us-gaap	Contract With Customer Liability Increase Decrease For Contract Acquired In Business Combination ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination	13000000	usd
	ctsh	Contract With Customer Liability Foreign Currency Translation ContractWithCustomerLiabilityForeignCurrencyTranslation	0	usd
	ctsh	Contract With Customer Liability Foreign Currency Translation ContractWithCustomerLiabilityForeignCurrencyTranslation	2000000	usd
CY2024Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	420000000	usd
CY2023Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	410000000	usd
CY2024Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	4442000000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	32000000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	43000000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	5000000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	9000000	usd
	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	4000000	usd
	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	15000000	usd
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	33000000	usd
CY2024Q2	us-gaap	Short Term Investments ShortTermInvestments	12000000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	14000000	usd
CY2024Q2	us-gaap	Long Term Investments LongTermInvestments	86000000	usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	435000000	usd
CY2023Q4	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	96000000	usd
CY2024Q2	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	0	usd
CY2023Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	3000000	usd
CY2023Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	3000000	usd
CY2024Q2	us-gaap	Equity Method Investments EquityMethodInvestments	80000000	usd
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	74000000	usd
CY2023Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	6000000	usd
CY2024Q2	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	6000000	usd
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1163000000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1511000000	usd
CY2024Q2	ctsh	Customer Volumeand Other Incentives Current CustomerVolumeandOtherIncentivesCurrent	280000000	usd
CY2023Q4	ctsh	Customer Volumeand Other Incentives Current CustomerVolumeandOtherIncentivesCurrent	241000000	usd
CY2024Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	22000000	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	27000000	usd
CY2024Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	146000000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	146000000	usd
CY2024Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	465000000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	500000000	usd
CY2024Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	2076000000	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	2425000000	usd
CY2024Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	590000000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	606000000	usd
CY2024Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.227
CY2023Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.211
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.237
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.213
CY2023Q4	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	96000000	usd
CY2024Q2	us-gaap	Derivative Fair Value Of Derivative Asset Amount Not Offset Against Collateral DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral	38000000	usd
CY2024Q2	us-gaap	Derivative Fair Value Of Derivative Liability Amount Not Offset Against Collateral DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral	2000000	usd
CY2023Q4	us-gaap	Derivative Fair Value Of Derivative Asset Amount Not Offset Against Collateral DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral	20000000	usd
CY2023Q4	us-gaap	Derivative Fair Value Of Derivative Liability Amount Not Offset Against Collateral DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral	15000000	usd
	us-gaap	Cash Flow Hedge Gain Loss To Be Reclassified Within Twelve Months CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths	22000000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-74000000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	708000000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	577000000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	1403000000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	1279000000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1009000000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1048000000	usd
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
ctsh-20240630_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
0001058290-24-000242-index-headers.html	Edgar Link	pending
0001058290-24-000242-index.html	Edgar Link	pending
0001058290-24-000242.txt	Edgar Link	pending
0001058290-24-000242-xbrl.zip	Edgar Link	pending
ctsh-20240630.htm	Edgar Link	pending
ctsh-20240630.xsd	Edgar Link	pending
ctsh-20240630_g1.jpg	Edgar Link	pending
ctsh-20240630_g10.jpg	Edgar Link	pending
ctsh-20240630_g11.jpg	Edgar Link	pending
ctsh-20240630_g12.jpg	Edgar Link	pending
ctsh-20240630_g13.jpg	Edgar Link	pending
ctsh-20240630_g14.jpg	Edgar Link	pending
ctsh-20240630_g15.jpg	Edgar Link	pending
ctsh-20240630_g16.jpg	Edgar Link	pending
ctsh-20240630_g17.jpg	Edgar Link	pending
ctsh-20240630_g18.jpg	Edgar Link	pending
ctsh-20240630_g19.jpg	Edgar Link	pending
ctsh-20240630_g2.jpg	Edgar Link	pending
ctsh-20240630_g20.jpg	Edgar Link	pending
ctsh-20240630_g21.jpg	Edgar Link	pending
ctsh-20240630_g22.jpg	Edgar Link	pending
ctsh-20240630_g23.jpg	Edgar Link	pending
ctsh-20240630_g24.jpg	Edgar Link	pending
ctsh-20240630_g25.jpg	Edgar Link	pending
ctsh-20240630_g26.jpg	Edgar Link	pending
ctsh-20240630_g27.jpg	Edgar Link	pending
ctsh-20240630_g28.jpg	Edgar Link	pending
ctsh-20240630_g29.jpg	Edgar Link	pending
ctsh-20240630_g3.jpg	Edgar Link	pending
ctsh-20240630_g30.jpg	Edgar Link	pending
ctsh-20240630_g4.jpg	Edgar Link	pending
ctsh-20240630_g5.jpg	Edgar Link	pending
ctsh-20240630_g6.jpg	Edgar Link	pending
ctsh-20240630_g7.jpg	Edgar Link	pending
ctsh-20240630_g8.jpg	Edgar Link	pending
ctsh-20240630_g9.jpg	Edgar Link	pending
ctshexhibit1016302024.htm	Edgar Link	pending
ctshexhibit1026302024.htm	Edgar Link	pending
ctshexhibit1026302024001.jpg	Edgar Link	pending
ctsh-20240630_def.xml	Edgar Link	unprocessable
ctsh-20240630_htm.xml	Edgar Link	completed
ctsh-20240630_lab.xml	Edgar Link	unprocessable
ctsh-20240630_pre.xml	Edgar Link	unprocessable
ctshexhibit1026302024002.jpg	Edgar Link	pending
ctshexhibit1026302024003.jpg	Edgar Link	pending
ctshexhibit1026302024004.jpg	Edgar Link	pending
ctshexhibit1026302024005.jpg	Edgar Link	pending
ctshexhibit1026302024006.jpg	Edgar Link	pending
ctshexhibit1026302024007.jpg	Edgar Link	pending
ctshexhibit1026302024008.jpg	Edgar Link	pending
ctshexhibit1026302024009.jpg	Edgar Link	pending
ctshexhibit1026302024010.jpg	Edgar Link	pending
ctshexhibit1026302024011.jpg	Edgar Link	pending
ctshexhibit1026302024012.jpg	Edgar Link	pending
ctshexhibit1026302024013.jpg	Edgar Link	pending
ctshexhibit1026302024014.jpg	Edgar Link	pending
ctshexhibit1026302024015.jpg	Edgar Link	pending
ctshexhibit1026302024016.jpg	Edgar Link	pending
ctshexhibit1026302024017.jpg	Edgar Link	pending
ctshexhibit1026302024018.jpg	Edgar Link	pending
ctshexhibit1026302024019.jpg	Edgar Link	pending
ctshexhibit1026302024020.jpg	Edgar Link	pending
ctshexhibit1026302024021.jpg	Edgar Link	pending
ctshexhibit1026302024022.jpg	Edgar Link	pending
ctshexhibit1026302024023.jpg	Edgar Link	pending
ctshexhibit1026302024024.jpg	Edgar Link	pending
ctshexhibit1026302024025.jpg	Edgar Link	pending
ctshexhibit1026302024026.jpg	Edgar Link	pending
ctshexhibit1026302024027.jpg	Edgar Link	pending
ctshexhibit1026302024028.jpg	Edgar Link	pending
ctshexhibit1026302024029.jpg	Edgar Link	pending
ctshexhibit1026302024030.jpg	Edgar Link	pending
ctshexhibit1026302024031.jpg	Edgar Link	pending
ctshexhibit1026302024032.jpg	Edgar Link	pending
ctshexhibit1026302024033.jpg	Edgar Link	pending
ctshexhibit1026302024034.jpg	Edgar Link	pending
ctshexhibit1026302024035.jpg	Edgar Link	pending
ctshexhibit1026302024036.jpg	Edgar Link	pending
ctshexhibit1026302024037.jpg	Edgar Link	pending
ctshexhibit1026302024038.jpg	Edgar Link	pending
ctshexhibit1026302024039.jpg	Edgar Link	pending
ctshexhibit1026302024040.jpg	Edgar Link	pending
ctshexhibit1026302024041.jpg	Edgar Link	pending
ctshexhibit1026302024042.jpg	Edgar Link	pending
ctshexhibit1026302024043.jpg	Edgar Link	pending
ctshexhibit1026302024044.jpg	Edgar Link	pending
ctshexhibit1026302024045.jpg	Edgar Link	pending
ctshexhibit1026302024046.jpg	Edgar Link	pending
ctshexhibit1026302024047.jpg	Edgar Link	pending
ctshexhibit1026302024048.jpg	Edgar Link	pending
ctshexhibit1026302024049.jpg	Edgar Link	pending
ctshexhibit1026302024050.jpg	Edgar Link	pending
ctshexhibit1026302024051.jpg	Edgar Link	pending
ctshexhibit1026302024052.jpg	Edgar Link	pending
ctshexhibit1026302024053.jpg	Edgar Link	pending
ctshexhibit1026302024054.jpg	Edgar Link	pending
ctshexhibit1026302024055.jpg	Edgar Link	pending
ctshexhibit1026302024056.jpg	Edgar Link	pending
ctshexhibit1026302024057.jpg	Edgar Link	pending
ctshexhibit1026302024058.jpg	Edgar Link	pending
ctshexhibit1026302024059.jpg	Edgar Link	pending
ctshexhibit1026302024060.jpg	Edgar Link	pending
ctshexhibit1026302024061.jpg	Edgar Link	pending
ctshexhibit1026302024062.jpg	Edgar Link	pending
ctshexhibit1026302024063.jpg	Edgar Link	pending
ctshexhibit1026302024064.jpg	Edgar Link	pending
ctshexhibit1026302024065.jpg	Edgar Link	pending
ctshexhibit1026302024066.jpg	Edgar Link	pending
ctshexhibit1026302024067.jpg	Edgar Link	pending
ctshexhibit1026302024068.jpg	Edgar Link	pending
ctshexhibit1026302024069.jpg	Edgar Link	pending
ctshexhibit1026302024070.jpg	Edgar Link	pending
ctshexhibit1026302024071.jpg	Edgar Link	pending
ctshexhibit1026302024072.jpg	Edgar Link	pending
ctshexhibit1026302024073.jpg	Edgar Link	pending
ctshexhibit1026302024074.jpg	Edgar Link	pending
ctshexhibit1026302024075.jpg	Edgar Link	pending
ctshexhibit1026302024076.jpg	Edgar Link	pending
ctshexhibit1026302024077.jpg	Edgar Link	pending
ctshexhibit1026302024078.jpg	Edgar Link	pending
ctshexhibit1026302024079.jpg	Edgar Link	pending
ctshexhibit1026302024080.jpg	Edgar Link	pending
ctshexhibit1026302024081.jpg	Edgar Link	pending
ctshexhibit1026302024082.jpg	Edgar Link	pending
ctshexhibit1026302024083.jpg	Edgar Link	pending
ctshexhibit1026302024084.jpg	Edgar Link	pending
ctshexhibit1026302024085.jpg	Edgar Link	pending
ctshexhibit1026302024086.jpg	Edgar Link	pending
ctshexhibit1026302024087.jpg	Edgar Link	pending
ctshexhibit1026302024088.jpg	Edgar Link	pending
ctshexhibit1026302024089.jpg	Edgar Link	pending
ctshexhibit1026302024090.jpg	Edgar Link	pending
ctshexhibit1026302024091.jpg	Edgar Link	pending
ctshexhibit1026302024092.jpg	Edgar Link	pending
ctshexhibit1026302024093.jpg	Edgar Link	pending
ctshexhibit1026302024094.jpg	Edgar Link	pending
ctshexhibit1026302024095.jpg	Edgar Link	pending
ctshexhibit1026302024096.jpg	Edgar Link	pending
ctshexhibit1026302024097.jpg	Edgar Link	pending
ctshexhibit1026302024098.jpg	Edgar Link	pending
ctshexhibit1026302024099.jpg	Edgar Link	pending
ctshexhibit1026302024100.jpg	Edgar Link	pending
ctshexhibit1026302024101.jpg	Edgar Link	pending
ctshexhibit1026302024102.jpg	Edgar Link	pending
ctshexhibit1026302024103.jpg	Edgar Link	pending
ctshexhibit1026302024104.jpg	Edgar Link	pending
ctshexhibit1026302024105.jpg	Edgar Link	pending
ctshexhibit1026302024106.jpg	Edgar Link	pending
ctshexhibit1026302024107.jpg	Edgar Link	pending
ctshexhibit1026302024108.jpg	Edgar Link	pending
ctshexhibit1026302024109.jpg	Edgar Link	pending
ctshexhibit1026302024110.jpg	Edgar Link	pending
ctshexhibit1026302024111.jpg	Edgar Link	pending
ctshexhibit1026302024112.jpg	Edgar Link	pending
ctshexhibit1026302024113.jpg	Edgar Link	pending
ctshexhibit1026302024114.jpg	Edgar Link	pending
ctshexhibit1026302024115.jpg	Edgar Link	pending
ctshexhibit1026302024116.jpg	Edgar Link	pending
ctshexhibit1026302024117.jpg	Edgar Link	pending
ctshexhibit1026302024118.jpg	Edgar Link	pending
ctshexhibit1026302024119.jpg	Edgar Link	pending
ctshexhibit1026302024120.jpg	Edgar Link	pending
ctshexhibit1026302024121.jpg	Edgar Link	pending
ctshexhibit1026302024122.jpg	Edgar Link	pending
ctshexhibit1026302024123.jpg	Edgar Link	pending
ctshexhibit1026302024124.jpg	Edgar Link	pending
ctshexhibit1026302024125.jpg	Edgar Link	pending
ctshexhibit1026302024126.jpg	Edgar Link	pending
ctshexhibit1026302024127.jpg	Edgar Link	pending
ctshexhibit1026302024128.jpg	Edgar Link	pending
ctshexhibit1026302024129.jpg	Edgar Link	pending
ctshexhibit1026302024130.jpg	Edgar Link	pending
ctshexhibit3116302024.htm	Edgar Link	pending
ctshexhibit3126302024.htm	Edgar Link	pending
ctshexhibit3216302024.htm	Edgar Link	pending
ctshexhibit3226302024.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CTSH
COGNIZANT TECHNOLOGY SOLUTIONS CORP Stock $ctsh

2024 Q3 Form 10-Q Financial Statement

#000105829024000242 Filed on August 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTSH COGNIZANT TECHNOLOGY SOLUTIONS CORP Stock $ctsh

2024 Q3 Form 10-Q Financial Statement

#000105829024000242 Filed on August 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTSH
COGNIZANT TECHNOLOGY SOLUTIONS CORP Stock $ctsh